Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
The DOI matches its Crossref record; 158 of the 169 references it cites were found in a registry or an index.
Abstract
Objective: To update the "Testosterone Therapy in Men With Androgen Deficiency Syndromes" guideline published in 2010. Participants: The participants include an Endocrine Society-appointed task force of 10 medical content experts and a clinical practice guideline methodologist. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees and members and the cosponsoring organization were invited to review and comment on preliminary drafts of the guideline. Conclusions: We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone-binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level > 4 ng/mL, prostate-specific antigen > 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRT is also contra-indicated in people with (high risk of) prostate cancer, a history of breast cancer, thrombophilia, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, and myocardial infarction or stroke within the last 6 months [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It suppresses spermatogenesis, and thus, cannot be used in patients with a desire to have children in the near future.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It may result in gynecomastia, acne, testicular atrophy and erythrocytosis.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“The Endocrine Society guideline emphasizes the importance of lifestyle changes in men with central hypogonadism and comorbidities [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“Hyperprolactinemia also suppresses the secretion of GnRH and the response of gonadotropins to GnRH secretion.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
Self-citationAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationHeidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 1×
“culated from TT, SHBG, and albumin levels (23, 24).”
Harrison's Principles of Internal Medicine
Massarelli, J. J. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340300091039 · Cited by 1,132
Research works printed but not linked: 1
- Bhasin, 2015, Disorders of the testes and male reproductive system
Cited by
Items 1,301–1,400 of 1,733
When a “Low T” Diagnosis Can Be the Clue to a More Complex Problem
Dumitrascu, A. G., Chindris, A.-M., Matei, C., & Chirilă, R. M. (2023) · Cureus · doi:10.7759/cureus.51215
“…deficiency, functional hypogonadism causes (hyperprolactinemia, alcohol, and marijuana abuse, glucocorticoids, opioids, anabolic steroid use, severe obesity and obstructive sleep apnea, chronic systemic illnesses, or severe nutritional deficiencies/excessive exercise) should be ruled out first [4].”
BackgroundInfluentialAssessment of reproductive hormones in infertile males
Salvio, G., Firmani, F., & Balercia, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93047-5.00022-2
Andersen, M. L., SANCHES, J. B., Alvarenga, T. A., Toricelli, M., Vasco, M. B., & Tufik, S. E. R. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02981-6
Reproductive and nonreproductive actions of testosterone
Gagliano‐Jucá, T., Jain, A., Jasuja, R., & Bhasin, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00198-9
Self-citationIpogonadismo metabolico maschile: una forma di ipogonadismo funzionale nell’uomo obeso
Guadagnino, L., Cannarella, R., & Calogero, A. E. (2026) · L Endocrinologo · doi:10.1007/s40619-026-01823-0
“…metabolico rappresenta una condizione po-tenzialmente reversibile di soppressione dell’asse IIT asso-ciata a ipogonadismo funzionale; pertanto, la gestione tera-peutica dovrebbe prioritariamente basarsi su interventi sullo stile di vita finalizzati alla riduzione del peso corporeo [11].”
InfluentialJiang, H., Li, B., Jin, D., Zhong, Q.-L., Zhu, T., & 李彦锋 (2025) · Translational Andrology and Urology · doi:10.21037/tau-2025-199 · Cited by 1
Naber, W. C., Brandt, R. B., Leon-Grooters, M., van der Wal, R., van den Berg, S. A. A., Goeman, J. J., MaassenVanDenBrink, A., & Fronczek, R. (2026) · Headache The Journal of Head and Face Pain · doi:10.1111/head.70174
Testosterone in Relapsing–Remitting Multiple Sclerosis: A Case–Control Study
Rościszewska-Żukowska, I., Popiel, M., Perenc, A., Rudnicka-Czerwiec, J., Malska, I., & Bartosik-Psujek, H. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124401
“The free fraction and, to some extent, the albumin fraction represent the biologically active component, capable of penetrating cells and exerting their effects through the androgen receptor [7,8].”
Chapter 2: Fundamentals of Pharmacy Practice
Hohmeier, K. C. (2026) · doi:10.21019/9781582123875.ch2
Endocrine Testing and the Association Between Varicocele and Hypogonadism
Yaguchi, G., & Dabaja, A. A. (2019) · Springer eBooks · doi:10.1007/978-3-319-79102-9_13 · Cited by 2
Campana, C., Casabella, A., Arecco, A., Cutolo, M., Tonelli, S., Hysa, E., Vera, L., Bertaina, F., Amarù, J., Ferone, D., et al. (2026) · Pituitary · doi:10.1007/s11102-026-01696-4
Shelton, C. M. (2022) · The American Pharmacists Association eBooks · doi:10.21019/9781582123615.ch36
Exogenous Hormone Therapy and Hyperprolactinemia
Herndon, J. S. (2024) · Physician Assistant Clinics · doi:10.1016/j.cpha.2024.02.007
Maurer, G. D., & Steinbach, J. P. (2021) · Elsevier eBooks · doi:10.1016/b978-3-437-23824-6.00059-6
Stump, K., Aynaszyan, S., Totis, F., Pazionis, T. J. C., & Passias, P. G. (2026) · Spine Open · doi:10.1097/bn9.0000000000000121
Keimzellneoplasie in situ (GCNIS): Therapie
Dieckmann, K., & Heidenreich, A. (2019) · Springer Reference Medizin · doi:10.1007/978-3-662-54652-9_64-1
Testosterone Therapy: Do American and European Clinicians Have Different Approaches?
Trost, L. W., & Zitzmann, M. (2018) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2018.07.010
Total testosterone levels in men with acute coronary syndrome
Shishkov, S. R., Hristozov, K., Boyadzhieva, M., & Slavcheva, S. E. (2022) · Scripta Scientifica Medica · doi:10.14748/ssm.v54i4.8662
CONSTANTINOU, B. T., BENEDICTO, B. C., Galligani, L., Schiavon, B. N., Mendes, C. M. O., Petri, M. M. G., Uzueli, B., Maia, R. S., Sardenberg, R. A. S., Fraietta, R., et al. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04134-3
Sun, G. (2026) · Springer eBooks · doi:10.1007/978-3-031-90919-1_33-1
Gonadotropins and testicular function in aging
Chen, Y., Yuen, F., Wang, C., Liu, P. Y., & Swerdloff, R. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00125-4
Self-citationClassification and Epidemiology of Hypogonadism
Billa, E., Kanakis, G., & Goulis, D. G. (2026) · Endocrinology · doi:10.1007/978-3-319-29456-8_22-2
Beltrán, C. S. G., García-Perdomo, H. A., & Ramos, A. F. G. (2026) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2026.501935
Chapter 40: Menopause and Contraception
Hagemann, T. M. (2026) · doi:10.21019/9781582123875.ch40
Hypogonadism among Type 2 Diabetes Mellitus Patients with Male Erectile Dysfunction
Kadhim, D. J., Almomin, A., & Mansour, A. A. (2023) · Ibnosina Journal of Medicine and Biomedical Sciences · doi:10.1055/s-0043-1769493 · Cited by 2
Warren, S. (2026) · Cureus · doi:10.7759/cureus.109299
“All blood draws were performed in the fasting state, in the morning (before 10:00 AM), consistent with Endocrine Society recommendations for testosterone measurement [19].”
The Potential for Pharmacological Interventions for Low Sex Drive in Men
Reddy, A. G., Khoei, A. A., & Khera, M. (2022) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2021.12.005
de Velasco, L. M. C., Flores, J. E. G., Kraus-Fischer, G., de la Vega, M., Arteaga, J. L. M., Margalef, A. B., Mora, S. S., Abruch-Fleisher, A., & Cervera, A. A. (2026) · Cureus · doi:10.7759/cureus.109931
“…that adequate testosterone levels contribute to the maintenance of skeletal muscle mass, improved muscle function, and favorable metabolic profiles, emphasizing the importance of androgen signaling in the preservation of lean tissue and the prevention of excess fat accumulation [17,18,19].”
Management of the interaction between the multiple pituitary hormone deficiencies
Feldt‐Rasmussen, U., Effraimidis, G., Rasmussen, Å. K., & Klose, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00392-7
Schuppe, H.-C., & Köhn, F. (2021) · Springer eBooks · doi:10.1007/978-3-662-58713-3_83-1
Testicular Function and Skeletal Alterations
Ferlin, A. (2020) · Trends in andrology and sexual medicine · doi:10.1007/978-3-319-96376-1_8
Interpretation of the endocrinology of hospital inpatients
Hanafy, A., Seejore, K., Lynch, J. M., & Murray, R. D. (2021) · British Journal of Hospital Medicine · doi:10.12968/hmed.2020.0517
Чоловічий фактор безпліддя: алгоритм лабораторної діагностики причин (частина 2)
Рыкова, О. В. (2019) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.15.3.2019.172111
Männlicher Hypogonadismus und Alterung: ein Update
Iglesias, P., Núñez, A., & Díez, J. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-65245-5_9 · Cited by 1
Sleep, Circadian Rhythms, and Male Reproduction
Liu, P. Y. (2026) · Endocrinology · doi:10.1007/978-3-319-29456-8_64-1
Renardson, L., Bari, H., & Ahmad, J. (2026) · BMJ Case Reports · doi:10.1136/bcr-2025-270444
Hamdy, R. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99550-4.00008-3
Valencia, W. M., & Florez, H. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-76271-1_20
Vignera, S. L., & Condorelli, R. A. (2026) · Nutrients · doi:10.3390/nu18152417
“Given the reversible nature of MOSH—in contrast to organic hypogonadism—lifestyle interventions, particularly dietary modifications, represent the primary therapeutic strategy before considering testosterone replacement therapy (TRT) [13,14].”
Chapter 8: Biotechnology and Pharmacogenomics
Elchynski, A. L. (2026) · doi:10.21019/9781582123875.ch8
Testosterone Therapy in Men with Functional Hypogonadism
Mauvais‐Jarvis, F. (2025) · Springer eBooks · doi:10.1007/978-3-031-89650-7_15
Wu, T., Guo, J., Zhuang, W., et al. (2026) · Talanta · doi:10.1016/j.talanta.2026.130131
Paez-Allendes, L., Valenzuela-Fuenzalida, J. J., Moya, M. P., Oyanedel, G., Cifuentes-Suazo, G., Figueroa-Puig, J., Orellana-Donoso, M., Mateluna-Valls, E., Cabezas-Salgado, J. J., Sanchis-Gimeno, J., et al. (2026) · Nutrients · doi:10.3390/nu18132090
Testosterone Deficiency and Changes in Body Composition in Men Living with HIV
Antunes, L. D. S., Soares, L. H. M., Abreu, J. M., Nogueira, A. B. B., Velarde, L. G. C., Filho, R. A. D. C., Lima, G. A. B., & Soares, D. V. (2025) · The Open AIDS Journal · doi:10.2174/0118746136393522251003053028 · Cited by 1
Krikelis, M. I., Divaris, E., Pappa, A., Kassi, E., Anagnostis, P. G., & Tournis, S. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109125
Nguyen, H. T., Nguyen, A. L. K., Tran, C. Q., Dam, C. V., Nguyen, T. H., & Nguyen, T. K. (2026) · Andrologia · doi:10.1155/and/8818332
The most prominent terminological problems in reproductive medicine
Andreeva, E. N., Mel'nichenko, G. A., Grigoryan, O. R., Rozhivanov, R. V., Михеев, Р. К., Чернова, М. О., & Романовна, Р. Е. (2024) · Bulletin of Reproductive Health · doi:10.14341/brh12737
The effects of bupropion treatment on libido and hormones
Şen, Ç. Ç., Çıkma, M., Yildiz, N., Garip, Z., Kirmit, A., & Gülersoy, E. (2025) · Comparative Clinical Pathology · doi:10.1007/s00580-025-03700-y
“In low libido and male hypogonadism, testosterone therapy is often preferred (Bhasin et al. 2018; Chung 2019; Salter and Mulhall 2019).”
Management of Acromegaly associated Late-onset hypogonadism by Siddha medicine: A case report
Subramani, B., & Sathiyarajeswaran, P. (2022) · International Journal of Ayurvedic Medicine · doi:10.47552/ijam.v13i1.2337
Sexual Function and Libido Loss in Female Climbers—A Cross-Sectional Study
Vollrath, S., Koller, A.-S., Bitterlich, N., Buadze, A., Schwartz, A. K., Stute, P., Hackney, A. C., & Werth, N. (2026) · Sports · doi:10.3390/sports14060242 · Cited by 1
Maltese, V., Delbarba, A., Gatta, E., Vetrugno, S., Sansone, A., & Cappelli, C. (2026) · Endocrine · doi:10.1007/s12020-026-04659-8
“Current recommendations also focus exclusively on peak assessment, advising that TT levels be measured 2–8 h after gel application [1, 3 ], while offering no indications regarding nadir measurements.”
InfluentialLa sindrome di Klinefelter: gestione clinica
Forestiere, D., Carotenuto, R. M., Selvaggio, L. D., Fraia, R. D., Allosso, F., & Pasquali, D. (2021) · L Endocrinologo · doi:10.1007/s40619-021-00977-3
Relative Energy Deficiency in an Elite Nonendurance Male Athlete: A Case Report
Zhou, Y., Gu, N., Wang, W., Gao, Y., & Zhang, J. (2021) · Current Sports Medicine Reports · doi:10.1249/jsr.0000000000000906
Ružić, L., Rakovac, M., Bilić-Čurčić, I., Jakovac, D., & Berković, M. C. (2025) · Healthcare · doi:10.3390/healthcare13182328 · Cited by 1
“In aging athletes, particularly those with a history of anabolic steroid use, TRT should be approached with great caution [58,62].”
Effect of Opioids on Adrenal and Reproductive Endocrinology
Armeni, E., Grossman, A. B., & Khoo, B. C. E. (2022) · doi:10.1093/med/9780198870197.003.0211
Cardiovascular safety of testosterone replacement therapy
Čapka, D. (2023) · Urologie pro praxi · doi:10.36290/uro.2023.070
Testosterone Replacement Therapy: Indications, Application Protocols, and Side Effect Profile
Demir, E., & Akpınar, E. (2026) · Recent trends in pharmacology. · doi:10.62425/rtpharma.1829150 · Cited by 1
Li, C., Zhang, Y.-X., Yang, X., Wang, Y., Zhao, H., & Feng, J. (2025) · BMC Biotechnology · doi:10.1186/s12896-025-01067-0
“Aging is a critical risk factor for OSA [4, 5].”
Chapter 14: Stable Atherosclerotic Disease
Gibson, C. M., & Rogers, K. C. (2026) · doi:10.21019/9781582123875.ch14
Low testosterone is a phenotype of visceral adiposity
Friedl, K. E., & Potter, A. W. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag160 · Cited by 1
Bonenti, B., Puljević, C., Ferris, J., Davies, E., WINSTOCK, A. R., Shorter, G. W., Ganson, K. T., Barnett, A., Nagata, J. M., & Piatkowski, T. M. (2026) · Alcohol and Alcoholism · doi:10.1093/alcalc/agag047
Hypopituitarism in Adults: Rational Approaches to Diagnosis and Treatment
Almalki, M. (2023) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0043-1768587
Schuppe, H., Köhn, F., & Linn, T. (2022) · Springer Reference Medizin · doi:10.1007/978-3-642-41168-7_156-2
Wang, X., 应志康, Guo, H., Zhang, X., & Jiang, D. (2026) · Middle East Fertility Society Journal · doi:10.1186/s43043-026-00348-8 · Cited by 1
Voinea, R.-A., Ronger, L., Martínez, A., & Tauveron, I. (2026) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(26)52261-x
Chapter 35: Infectious Diseases
Hawkins, B. K. (2026) · doi:10.21019/9781582123875.ch35
Karczewska, K., Ziółek, M. A., Domagała, K., Maroszek, M., Szymczak, K., Janik, B., Bakier, A., Kuniewicz, J., Tokarczyk, M., Kuczkowska, J. M., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5457
Testosterone Therapy: Oral Androgens
Kalinchenko, S. Y., Tyuzikov, I. A., Mskhalaya, G. J., & Tishova, Y. (2023) · Springer eBooks · doi:10.1007/978-3-031-31501-5_13 · Cited by 1
Ghai, R., Chauhan, K., Nagarajana, K., Ali, N., Mani, K., Kapoor, G., Pandey, A., & Verma, V. (2024) · Current Bioactive Compounds · doi:10.2174/0115734072320845241203051313
Reid, K. F., Storer, T. W., Pencina, K. M., Ghattas, C., Shang, Y. V., Gavin, C., Valderrábano, R. J., Latham, N. K., Bracken, E. M., Lemay, L., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag173
Self-citationAspects of hypogonadism in oncological patients receiving antitumor treatment. Literature review
Abramov, M. Е., Israelyan, E. R., Tsareva, А. S., Rumyantsev, А. А., Firsov, K. A., & Matveev, V. B. (2025) · Cancer Urology · doi:10.17650/1726-9776-2025-21-1-119-125
Hypogonadism in Men with Obesity and Type 2 Diabetes
Dhindsa, S., Ghanim, H., & Dandona, P. (2025) · Springer eBooks · doi:10.1007/978-3-031-89650-7_18
Akçura, C., Güney, S. C., Alkan, S., et al. (2023) · Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi · doi:10.34087/cbusbed.1186909
Treatment of male hypogonadism with clomiphene citrate- where do we stay?
Manov, A. E., & Benge, E. (2022) · GSC Advanced Research and Reviews · doi:10.30574/gscarr.2022.13.1.0272
HIPOGONADISMO MASCULINO E SUA RELAÇÃO COM A SINDROME METABÓLICA
Pinto, J. C., & da Costa, R. S. L. (2024) · Revista Foco · doi:10.54751/revistafoco.v17n1-079 · Cited by 2
Wu, J., Chen, J., Tao, Y., Guo, Q., Huang, J., Zhang, Y., Zhang, T., Mo, Z., Wang, D., Xu, T., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04574-0
“[34 , 35].”
Associations of Serum Testosterone and 25-Hydroxyvitamin D with Bone Mineral Density in Aging Men
Bae, W. J., Kim, S.-M., Lee, H. J., Huh, W., & Lee, D. S. (2026) · The World Journal of Men s Health · doi:10.5534/wjmh.260018
Epidemiologic Features and Management of Sexual Dysfunctions in Infertile Men
Huyghe, É., & Chiu, P. K. (2024) · Springer eBooks · doi:10.1007/978-3-031-62648-7_13
Fedai, N. K., Uzun, N., Bostan, H., Kızılgül, M., Demirci, T., Çakal, E., & Uçan, B. (2026) · HORMONES · doi:10.1007/s42000-026-00766-3 · Cited by 1
Slipped Bilateral Capital Femoral Epiphysis in a Patient Older Than 25 Case Report
Sosa, M., Rey, R., Lemus, E., Agüero, D. P., & Mendoza, P. D. B. (2023) · International Journal of Medical Science and Clinical Research Studies · doi:10.47191/ijmscrs/v3-i8-09
Hipogonadismo masculino secundario a macroprolactinoma
Arias, J., & Agüero, P. (2023) · Revista Médica del Uruguay · doi:10.29193/rmu.39.1.14
Testosterone Replacement in Hypogonadic Men
Alves, M. L. D. ́. (2022) · Journal of Medical - Clinical Research & Reviews · doi:10.33425/2639-944x.1278
“TTh does not cause a worsening of lower urinary tract symptoms or sleep apnea [16].”
BackgroundMaurer, G. D., & Steinbach, J. P. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21011-2.00060-0
Papież, Ł. S., Dołęga, J., Zabawa, B., Krzykawski, K., Maciejczyk, T., Sieńko, A., Hudzińska, P., Sadowski, J., Mól, P., & Łabuś, M. (2024) · Quality in Sport · doi:10.12775/qs.2024.34.56223
“It has been proven that weight loss, irrespective of diet, can improve testosterone levels, however keto's specific effectiveness on abdominal fat loss may be more beneficial[65].”
Comparing Motivations for Anabolic-Androgenic Steroid Use Among an International Sample of Men
Ahmadinejad, B., Bonenti, B., Puljević, C., Ferris, J., WINSTOCK, A. R., Khan, I., Ball, L., FISHER, K., & Piatkowski, T. M. (2026) · Substance Use & Misuse · doi:10.1080/10826084.2026.2675989 · Cited by 1
Düğer, H. (2024) · Journal of Health Sciences and Medicine · doi:10.32322/jhsm.1387621 · Cited by 1
Rastrelli, G., Corona, G., & Maggi, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00107-2
Testosterone and Cardiovascular Disease
Goldman, A., & Bhasin, S. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_30
Self-citationPhysiotherapy and Rehabilitation in Andropause
Erbay, B., Tekin, G., & Üzelpasacı, E. (2026) · Springer eBooks · doi:10.1007/978-3-032-28741-0_22
Testosteron und kardiovaskuläre Effekte
Yeap, B. B. (2024) · Springer eBooks · doi:10.1007/978-3-031-65245-5_19
Trejo, P., & Martínez, C. (2025) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2025.07.002
Anaboler, steroidinduzierter Hypogonadismus
Hohl, A., Lee, S. V. D. S., & Ronsoni, M. F. (2024) · Springer eBooks · doi:10.1007/978-3-031-65245-5_12
Hernández, R. A., de Silva, N. L., Hudson, J., Cruickshank, M., Quinton, R., Manson, P. D., Dhillo, W. S., Bhattacharya, S., Brazzelli, M. G., & Jayasena, C. N. (2024) · Andrology · doi:10.1111/andr.13597 · Cited by 1
Whole plant Adiantum capillus-veneris linn extract as an anti-COVID-19 therapyPreprint
Hendawy, L. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/7259u
Kamijima, J., Ikeda, A., Charvat, H., Maruyama, K., Tomooka, K., Kawamura, R., Takata, Y., Osawa, H., Tatsukawa, M., Yoshida, M., et al. (2026) · Neuroepidemiology · doi:10.1159/000550694
Griffith, A., Perlman, A. I., Karr, T., Thompson, M. E., & Kolterman, O. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1754430
Male Fertility and Testosterone Therapy
Andino, J. J., & Dupree, J. M. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009197533.035
Metadata
- Authors
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Baylor College of Medicine (US)
- Massachusetts General Hospital (US)
- University of Southern California (US)
- VA Puget Sound Health Care System (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- University of Manchester (GB)
- Corresponding author
- Bhasin, Shalender
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-03-17
- Volume
- 103
- Issue
- 5
- Pages
- 1715-1744
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2791298691
- Cited by
- 1,736
- References
- 169
- Citations by year
- 2026: 263 · 2025: 196 · 2024: 198 · 2023: 199 · 2022: 240 · 2021: 221 · 2020: 201 · 2019: 157 · 2018: 56
- FWCI
- 126.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, male hypogonadism, androgen deficiency, sex hormone-binding globulin, secondary sexual characteristics, treatment monitoring, patient decision-making, pharmacokinetics, sleep apnea, thrombophilia, heart failure, lower urinary tract symptoms, fertility preservation
- MeSH terms
- Aged, Aged, 80 and over, Aging, Blood Chemical Analysis, Diagnostic Techniques, Endocrine, Endocrinology, Humans, Hypogonadism, Male, Middle Aged, Societies, Medical, Testosterone, Evidence-Based Medicine, Hormone Replacement Therapy, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.